Int J Gynecol Cancer. 2018 Feb;28(2):338-345. doi: 10.1097/IGC.0000000000001156.
Gestational choriocarcinoma is a malignant form of gestational trophoblastic disease that usually arises after a molar pregnancy, but may follow any antecedent pregnancy. Investigations in this rare cancer are limited. We evaluated the prognostic effects of age, race, and stage in choriocarcinomas diagnosed for 4 decades.
Patients diagnosed as having gestational choriocarcinoma between 1973 and 2014 from the Surveillance, Epidemiology, and End Results program were eligible. Relationships with overall survival and cancer-specific survival were evaluated using log-rank testing and Cox modeling. Multivariate analyses included adjustments for age, race, and stage.
There were 947 patients with choriocarcinoma including 403 non-Hispanic white (NHW) patients, 473 with distant stage, and 142 who died. Median age at diagnosis was 25 years for non-Hispanic black (NHB) patients and 35 years for Asian/Pacific Islanders (API) compared with 29 years for NHW patients (P = 0.0001). Five-year overall survival varied between 82% and 92% when diagnosed at the age of at least 40 years compared with less than 20 years (P < 0.0001), and from 85% to 95% in patients with distant vs local disease (P < 0.0001), respectively. Multivariate analysis demonstrated that age, race, and stage were independent predictors of mortality. Risk of death increased incrementally in patients diagnosed at 20 to 39 years of age (adjusted hazard ratio [aHR], 3.87; 95% confidence interval [CI], 1.69-8.86; P = 0.001) and at least 40 years of age (aHR, 7.18; 95% CI, 2.95-17.49; P < 0.0001) compared with 20 years or younger. Non-Hispanic black patients were the only racial group at higher risk of death compared with NHW patients (aHR, 1.86; 95% CI, 1.22-2.82; P < 0.004). Distant vs local disease added an additional risk of death (aHR, 2.43; 95% CI, 1.57-3.75; P < 0.0001) over that attributable to age at diagnosis and NHB race. Similar relationships to cancer-specific survival were also observed (P < 0.05).
Most patients with choriocarcinoma have excellent prognosis. However, NHB patients and patients who are diagnosed at the age of at least 20 years or have distant stage have significantly worse mortality.
绒癌是一种恶性的妊娠滋养细胞肿瘤,通常发生在葡萄胎之后,但也可能发生在任何先前的妊娠之后。对这种罕见癌症的研究有限。我们评估了 40 年来诊断出的绒癌中年龄、种族和分期的预后影响。
符合条件的是 1973 年至 2014 年间通过监测、流行病学和最终结果(SEER)计划诊断为绒癌的患者。使用对数秩检验和 Cox 模型评估与总生存期和癌症特异性生存期的关系。多变量分析包括年龄、种族和分期的调整。
共有 947 例绒癌患者,其中包括 403 例非西班牙裔白人(NHW)患者、473 例远处转移患者和 142 例死亡患者。非西班牙裔黑人(NHB)患者和亚洲/太平洋岛民(API)患者的中位诊断年龄为 25 岁,而 NHW 患者为 35 岁(P=0.0001)。诊断时年龄至少为 40 岁的患者 5 年总生存率为 82%至 92%,而年龄小于 20 岁的患者为 20%以下(P<0.0001),远处疾病患者与局部疾病患者的 5 年总生存率分别为 85%至 95%(P<0.0001)。多变量分析表明,年龄、种族和分期是死亡率的独立预测因素。诊断时年龄在 20 至 39 岁(调整后的危险比[aHR],3.87;95%置信区间[CI],1.69-8.86;P=0.001)和至少 40 岁(aHR,7.18;95%CI,2.95-17.49;P<0.0001)的患者死亡风险与 20 岁或以下的患者相比,呈递增趋势。与 NHW 患者相比,非西班牙裔黑人患者是唯一死亡风险更高的种族群体(aHR,1.86;95%CI,1.22-2.82;P<0.004)。与诊断时的年龄和 NHB 种族相比,远处疾病增加了额外的死亡风险(aHR,2.43;95%CI,1.57-3.75;P<0.0001)。与癌症特异性生存也观察到类似的关系(P<0.05)。
大多数绒癌患者预后良好。然而,NHB 患者和诊断时年龄至少 20 岁或有远处转移的患者死亡率显著更高。